Sick Economics

Searching For Healthy Profits In The Stock Market

Sick Economics. Healthcare Investing Tips & Analysis. Big Pharma, Biotech, Medical Devices, Healthcare REITs & More.

SICK PICKS


Our favorite biotech shares and healthcare investments in today’s stock market. Highlighting companies that stand to profit through medical innovation, mismatches in share price to market potential, or just plain great economics. (Stocks may be owned by the Sick Economist, or other commentators on this page.)

ADMA

In 2019, ADMA acquired a manufacturing facility to ensure better quality control of its formulations for patients with immune deficiencies. ADMA is now emerging from a period of intense investment in its infrastructure. The company is now growing revenue by manufacturing and marketing blood plasma products, including Ascensiv, a plasma therapy for patients who suffer from Primary Humoral Immunodeficiency. In the first half of the 2020, the company grew its revenue by 78%, to $18 million. ADMA aims to grow revenues exponentially, forecasting $250 million in revenue within the next five years.

finviz dynamic chart for  ADMA 

Click On Chart To Expand

MESO

This Australian company, listed on the NASDAQ stock exchange, seeks to treat a wide range of diseases through the creation of new kinds of cellular therapies. MESO currently has three phase III products in development. On August 14th, 2020, an FDA advisory committee voted 9-1 to recommend approval of Remestemcel-L as a novel treatment for graft vrs host disease in children. This vote puts Meso on track to launch its first FDA approved product in 2021. The company is also in advanced testing of new cellular therapies for severe Covid-19, lower back pain, and cardiovascular disease.

finviz dynamic chart for  MESO 

Click On Chart To Expand

MORF

Morphic Holding, Inc, is pioneering therapies that focus on integrins, a category of proteins that play a role in many chronic diseases of the autoimmune, cardiovascular and metabolic systems. The small biotech has recently expanded on a partnership with a Pharma Giant (ABBV). AbbVie has chosen to exercise a license option to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. We’ll be keeping a close eye on MORF over the coming months and years. If all goes well, MORF has a massive potential upside.

finviz dynamic chart for  MORF 

Click On Chart To Expand

BIOTECH INVESTING


Biotech investing means betting on scientific innovation. This space is dedicated to small cap biotech stocks, leading edge biotechnology research, and small stocks that have flown under the radar. Let’s talk about how you can turn innovation into profit.

HOW TO NAVIGATE BIOTECH INVESTING DURING THE 2020 ELECTION

Like it or not, election season is rapidly approaching. With the novel coronavirus and increased…

3 BIOTECH STOCKS THAT WOULD BENEFIT FROM A BLUE WAVE

This fall promises to be a very interesting time in American History. A hotly contested…

PATENT INFRINGEMENT AND MRNA: MODERNA CONFRONTS AN UNEXPECTED HURDLE

Moderna Therapeutics was one of the first movers in the race to develop a vaccine…

HEALTHCARE SERVICES


Modern healthcare equities comprise an intricate ecosystem of healthcare service providers in addition to makers of medicines and devices. Investment in insurance companies, hospitals, clinics, and many other service providers have yielded substantial profits while helping millions of people.

THREE STOCKS HURT BY THE CORONAVIRUS PANDEMIC

The coronavirus pandemic has negatively impacted numerous companies. Within the healthcare industry, three companies are…

GENEDRIVE, PLC: WILL TESTING FOR THE MASSES EQUAL MASSIVE PROFITS?

What if you could take a test for the Cornavirus in your doctor’s office and…

ENTER THE BEAST: COULD AN INVESTOR TRIPLE HER MONEY BY INVESTING IN UNITED HEALTHCARE, INC?

Over the last ten years, United Health Inc ($UNH) has delivered a mind boggling annual…

HEALTHCARE REITs


Healthcare Real Estate (REITs) are high yielding stocks in the healthcare industry. You can invest in nursing homes, medical office buildings and research labs. Learn a profitable and easy way to invest in healthcare real estate.

HIGH YIELD HEALTHCARE: AN INTERVIEW WITH JUSSI ASKOLA

Jussi Askola is the President of Leonberg Capital, a boutique investment research firm specializing in…

3 HEALTHCARE REITS FOR STEADY RETIREMENT INCOME

With the Fed reluctant to raise interest rates further, those in or near retirement may…

3 BEST HEALTHCARE VALUE STOCKS FOR 2019

Who doesn’t love a nice Christmas sale? Everyone loves to pick up some good bargains around the holidays. When we talk about spending money, every retailer in the world advertises their big deals. But when we talk about making money, those deals may not be so obvious…

CAPITAL EQUIPMENT


Robots, radiation cannons, and molecular imaging machines aren’t just the healthcare tech of the future; they are also the source of investor profit for many decades to come. Big machines can mean big profits for equity investors.

WILL INTUITIVE SURGICAL BE PERMANENTLY CRIPPLED BY THE PANDEMIC?

Intuitive Surgical has revolutionized the minimally invasive, robotic-assisted surgical space with their FDA approved da…

LARRY CULP’S ART OF THE DEAL: 3 BUSINESS LESSONS FROM GE’S BIOPHARMACEUTICAL SALE

In a surprise move, GE has agreed to sell it’s BioPharmaceutical Division to Danaher for…

LESS PAIN, MORE GAIN: TREATING SKIN CANCER WITH SENSUS HEALTHCARE INC.

90 Day Update:  Since our original profile, Sensus Healthcare, Inc ($SRTS) has only looked better…

Subscribe To The Rx Newsletter

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT